Bone Biologics

News Events

News Events Hero

Press Releases

  • March 25, 2019

    Bone Biologics Receives Human Research Ethics Committee (HREC) Approval for the First Center of a Multicenter Pilot Clinical Trial to Evaluate NB1 (NELL-1/DBX®) in Australia

    Bone Biologics Corp. (OTCQB:BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has announced that it received Human Research Ethics Committee (HREC) approval on March 20, 2019, for the first center of a multicenter pilot clinical trial to evaluate NB1 (NELL-1/DBX®) in 30 patients in Australia. The pilot study will evaluate the safety and effectiveness of NB1 in adult subjects with degenerative disc disease (DDD) at one level from L2-S1, who may also have up to Grade 1 spondylolisthesis or Grade 1 retrolisthesis at the involved level who undergo transforaminal lumbar interbody fusion (TLIF).

    Read More >
  • July 23, 2018

    Bone Biologics Completes $5.9 Million of Financing

    Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of $5.9 million funding; $3.9 million in equity and a $2 million credit facility.

    Read More >
  • March 29, 2018

    Bone Biologics Completes $500,000 of Financing

    Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of $500,000 funding with Orthofix Holding, Inc.

    Read More >
  • December 20, 2017

    Bone Biologics Release: New Preclinical Data For Spine Fusion Demonstrates Osteopromotive Properties

    Bone Biologics Corp. (OTC QB: BBLG), a developer of orthobiologic products for the spinal fusion, trauma and osteoporosis markets, today has announced that it has completed a preclinical study, which shows its rhNELL-1 growth factor effectively promotes bone formation in a phylogenetically advanced spine model. In addition, rhNELL-1 was shown to be well tolerated and there were no findings of inflammation.

    Read More >
  • August 23, 2017

    Bone Biologics Adds Osteoporosis and Trauma Indications to its Portfolio

    BURLINGTON, Mass., August 23, 2017 — Bone Biologics Corp (OTC: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has announced that it has expanded its Field of Use definition of the license agreement with the UCLA Technology Development Group on behalf of UC Regents for NELL-1. Additionally, Bone Biologics has entered into an exclusive license agreement with the UCLA Technology Development Group on behalf of UC Regents for the worldwide application of the NELL-1 protein for both osteoporosis and trauma through a technology transfer.
    Read More >
  • August 22, 2017

    Bone Biologics Completes $1.4 Million Round of Financing

    Bone Biologics (OTC: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of a $1.4 million funding round with Musculoskeletal Transplant Foundation and Hankey Capital, LLC.

    Read More >
  • August 03, 2017

    Bone Biologics Announces Appointment of Bret Hankey to Company’s Board of Directors

    Bone Biologics Corp. (OTCQB: BBLG) announced that Bret Hankey has joined the company’s board of directors.

    Read More >
  • July 24, 2017

    Bone Biologics Corporation Announces Commencement of a Private Placement of Securities

    Bone Biologics Corporation (OTCQB: BBLG) announced today that it has commenced a private offering of up to $10,000,000 of its securities. The securities will initially only be offered to persons who are either stockholders of the company or who are “accredited investors,” as defined in Regulation D under the Securities Act of 1933, as amended (the “Securities Act”).

    Read More >
  • July 06, 2016

    Bone Biologics Names Scott D. Boden, MD Chief Medical Advisor

    Bone Biologics Corporation announced the engagement of Scott D. Boden, MD as Chief Medical Advisor. Dr. Boden is a tenured Professor of Orthopaedic Surgery at the Emory University School of Medicine and serves as the Director of the Emory Orthopaedics & Spine Center, Vice Chair of Orthopaedics, CMO/CQO of The Emory University Orthopaedics & Spine Hospital, and Emory Healthcare Physician Director of Strategy and Development for Orthopaedics & Spine Programs. He is also the Clinical Director of the Whitesides Orthopedic Research Laboratory.

    Read More >
  • June 14, 2016

    Bone Biologics Announces Signing of Option to License Revolutionary Bone Growth Factor Nell-1 from UCLA for Use in Osteoporosis

    Bone Biologics (OTCQB: BBLG), an orthobiologic company focused on regenerative medicine, announced today the signing of an option agreement with UCLA, for an opportunity to exclusively license the use of the revolutionary bone growth factor Nell-1 in the treatment of osteoporosis.

    Read More >
  • February 29, 2016

    Bone Biologics Completes $5.75 Million Round Of Financing

    Bone Biologics (OTCQB: BBLG), an orthobiologic company focused on regenerative medicine, announced today the completion of a $5.75 million funding round with Musculoskeletal Transplant Foundation, OrthoFix Holdings, Inc. and Hankey Capital, LLC.

    Read More >
  • May 06, 2015

    Bone Biologics Corp Completes Financing With Hankey Capital, LLC

    EDISON, N.J., May 6, 2015 — Bone Biologics, Corp., (“Bone Biologics”) announced today the completion of a $2M funding round with Hankey Capital, LLC (“Hankey Capital”) of Los Angeles, CA. The company is developing a proprietary protein for use in bone regenerative medicine using the patented recombinant human protein known as UCB-1 (or NELL-1) for use with patients undergoing spinal fusion.
    Read More >

Publications

NOVEL WNT REGULATOR NEL-LIKE MOLECULE-1 ANTAGONIZES ADIPOGENESIS AND AUGMENTS OSTEOGENESIS INDUCED BY BONE MORPHOGENETIC PROTEIN-2

Shen J, James AW, Zhang X1, Pang S, Zara JN1, Asatrian G, Chiang M, Lee M, Khadarian K, Nguyen A, Lee KS, Siu RK, Tetradis S, Ting K, Soo C.
Am J Pathol 186(2): 2016

The differentiation factor NEL-like molecule-1 (NELL-1) has been reported as osteoinductive in multiple in vivo preclinical models. Bone morphogenetic protein (BMP)-2 is used clinically
for skeletal repair, but in vivo administration can induce abnormal, adipose-filled, poor quality bone. We demonstrate that NELL-1 combined with BMP2 significantly optimizes
osteogenesis in a rodent femoral segmental defect model by minimizing the formation of BMP2-induced adipose-filled cyst like bone. In vitro studies using the mouse bone marrow
stromal cell line M2-10B4 and human primary bone marrow stromal cells have confirmed that NELL-1 enhances BMP2-induced osteogenesis and inhibits BMP2-induced adipogenesis.
Importantly, the ability of NELL-1 to direct BMP2-treated cells toward osteogenesis and away from adipogenesis requires intact canonical Wnt signaling. Overall, these studies establish
the feasibility of combining NELL-1 with BMP2 to improve clinical bone regeneration and provide mechanistic insight into canonical Wnt pathway activity during NELL-1 and BMP2
osteogenesis. The novel abilities of NELL-1 to stimulate Wnt signaling and to repress adipogenesis may highlight new treatment approaches for bone loss in osteoporosis.


HPSCS AND NELL-1 SYNERGISTICALLY ENHANCE SPINAL FUSION IN OSTEOPOROTIC RATS

Lee S, Zhang X, Shen J, James A, Chung C, Hardy R, Li C, Girgius C, Zhang Y, Stoker D, Wang H, Wu B, Peault B, Ting K, Soo C. Stem Cells (2015) in Press.

A combination of hPSCs, a population of native mesenchymal stem cells prospectively isolated from adipose tissues, and NELL‐1, an osteoinductive protein, was used. Results showed successful spinal fusion in osteoporotic rats with minimal side effects such as osteoinductive protein therapeutic for spinal fusion procedures in osteoporotic conditions such as inflammation and fat tissue formation. This combinational therapy using hPSCs combined with NELL‐1 has the potential to be a novel stem cell


NELL-1 EXPRESSION IN BENIGN AND MALIGNANT BONE TUMORS

Shen J, LaChaud G, Khadarian K, Shretha S, Zhang X, Soo C, Ting K, James A. BioChem BioPhy Res Comm. (2015) 460: 368-374.

Among osteosarcoma subtypes, fibroblastic osteosarcoma demonstrated the highest expression of NELL-1. NELL-1 demonstrates diffuse and reliable expression in benign but not malignant bone-forming skeletal tumors.


1 2 16